Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 121-132 of 215 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 121-132 of 215 studies
-
Restore CFTR ProteinCompleted with Results
Safety Study of VX 809 in People with CF and Homozygous for Delta F508 Gene Mutation , protocol number Vertex VX08-809-101The purpose of this study was to evaluate the safety and tolerability, of lumacaftor (VX-809) in subjects with cystic fibrosis who have two copies of the F508del CFTR gene mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
31 days
-
-
Mucociliary ClearanceCompleted with Results
BALANCE-CF 1: Study of BI 1265162, a mucus clearance drug, in teens and adults with CF , protocol number BI-1399-0003This study evaluated the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
7 weeks
-
-
Mucociliary ClearanceCompleted with Results
SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002This study took place in Europe, Australia and the U.S. It evaluated the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in preschool children with CF.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
54 weeks
-
-
Mucociliary ClearanceCompleted with Results
Pulmozyme in 3-5 Year Old Children with CF , protocol number Genentech Z4240gThis study looked at the effect of Pulmozyme on preschool aged (3-5 year old) children.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
3
-
Length of Participation:
32 days
-
-
Mucociliary ClearanceCompleted with Results
Study of QBW276 in adults with CF , protocol number Novartis CQBW276X2201This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
6
-
Length of Participation:
14 days
-
-
Mucociliary ClearanceCompleted with Results
Phase 1b study of inhaled AZD5634 in adults with CF , protocol number AstraZeneca D6600C00002This study evaluated the safety and tolerability of the inhaled drug AZD5634 in people with CF. It also evaluated the effect of AZD5634 on improving the ability to clear mucus from the lungs (lung mucociliary clearance - MCC).
-
Age:
18 Years to 60 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
4
-
Length of Participation:
4 months
-
-
Mucociliary ClearanceCompleted with Results
Phase 2 study of VX-371 in people with CF who are currently taking lumacaftor/ivacaftor , protocol number Vertex VX-371-101This study evaluated the safety and effectiveness of the inhaled drug VX-371 (formerly P-1037) in combination with hypertonic saline in participants who have two copies of the F508del CFTR mutation and are taking lumacaftor/ivacaftor (Orkambi®).
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
12
-
Length of Participation:
98 days
-
-
Mucociliary ClearanceCompleted with Results
SHIP: Study of hypertonic saline in preschoolers , protocol number SHIP001The SHIP study evaluated the safety and effectiveness of hypertonic saline (7%) in pre-school children with CF.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
Less than 99%
-
Number of Visits:
6
-
Length of Participation:
54 weeks
-
-
Mucociliary ClearanceCompleted with Results
Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF) , protocol number Parion PS-G201This study evaluated the drug P-1037 and its effectiveness in combination with the drug hypertonic saline in people with CF. There was no restriction based on CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
4
-
Length of Participation:
5 weeks
-
-
Mucociliary ClearanceCompleted with Results
Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number Pharmaxis DPM-CF-303This study evaluated the safety and effectiveness of the inhaled drug, Bronchitol® (mannitol).
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
6 months
-
-
Mucociliary ClearanceCompleted with Results
Denufosol in People with CF ages 2 - 4 years , protocol number Inspire 08-116The purpose of this study was to look at the safety and tolerability of denufosol aerosolized three times a day in pediatric CF patients 2 to 4 years of age
-
Age:
2 Years to 4 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
2
-
Length of Participation:
10 days
-
-
Mucociliary ClearanceCompleted with Results
Inhaled Dry Powder Mannitol in Cystic Fibrosis , protocol number Pharmaxis DPM-CF-302This Phase 3 study looked at the safety and effectiveness of treatment with inhaled dry powder mannitol.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30 to 89%
-
Number of Visits:
7
-
Length of Participation:
52 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More